The Jules Stein Eye Institute, University of California, Los Angeles, CA, USA.
Central Valley Eye Medical Group, Stockton, CA, USA.
Eye (Lond). 2022 Aug;36(8):1553-1559. doi: 10.1038/s41433-021-01593-z. Epub 2021 Jul 9.
Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of active Thyroid eye disease (TED). The current study reviews its efficacy in chronic TED.
In this retrospective review, consecutive patients with chronic stable TED (>2 years), who had received ≥3 infusions of teprotumumab were included. All patients had measurements of proptosis, and calculation of the CAS and diplopia scores before and after therapy. Five-point strabismus scores were also calculated. Patients who had imaging within 4 months prior to therapy and 6 weeks post therapy underwent orbital 3D volumetric analysis.
Thirty-one patients met the inclusion criteria. The mean (SD) duration of TED was 81 months (56) and the mean (SD) number of infusions received by each patient was 7 (2). Mean (SD) reduction in proptosis for each study orbit was 3.5 mm (0.4) and 3 mm (0.3) for the fellow orbit. The CAS response was 90% for the study orbit and 87% for the fellow orbit. Of the 15 patients who had diplopia at baseline, 67% had a clinically significant response, while 47% had complete resolution following treatment. Following teprotumumab, mean (SD) reduction of muscle tissue was 2011 mm (1847) in the study orbit and 1620 mm (1759) in the fellow orbit. The mean (SD) reduction of fat volume was 2101 mm (1681) in the study orbit and 1370 mm (1181) in the fellow orbit.
Teprotumumab significantly reduces proptosis, inflammation, diplopia, strabismus and orbital soft tissue volume in patients with chronic TED.
Teprotumumab 是一种新型的 IGF-1R 抗体，最近的研究表明其可显著减轻甲状腺眼病（TED）的活动性体征。本研究回顾了其在慢性 TED 中的疗效。
在这项回顾性研究中，纳入了连续患有慢性稳定 TED（>2 年）且已接受≥3 次 teprotumumab 输注的患者。所有患者均接受了眼球突出度测量，并在治疗前后计算了 CAS 和复视评分。还计算了斜视五分制评分。在治疗前 4 个月内和治疗后 6 周内进行了眼眶 3D 容积分析的患者。
31 名患者符合纳入标准。TED 的平均（SD）病程为 81 个月（56），每位患者接受的平均（SD）输注次数为 7（2）次。每个研究眼的平均（SD）眼球突出度降低为 3.5mm（0.4），对侧眼为 3mm（0.3）。研究眼的 CAS 反应为 90%，对侧眼为 87%。在基线时有复视的 15 名患者中，67%有临床显著反应，47%在治疗后完全缓解。接受 teprotumumab 治疗后，研究眼的平均（SD）肌肉组织减少 2011mm（1847），对侧眼为 1620mm（1759）。研究眼的平均（SD）脂肪体积减少 2101mm（1681），对侧眼为 1370mm（1181）。
Teprotumumab 可显著降低慢性 TED 患者的眼球突出度、炎症、复视、斜视和眼眶软组织体积。
